<DOC>
	<DOCNO>NCT00003584</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Prednisone may help relieve symptoms patient recurrent and/or metastatic kidney cancer . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist vinorelbine estramustine without prednisone treat patient recurrent and/or metastatic kidney cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Prednisone Treating Patients With Recurrent and/or Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate response rate vinorelbine estramustine patient metastatic and/or recurrent renal cell carcinoma . II . Obtain pilot data explore value anti-inflammatory treatment management severe systemic symptom improvement treatment tolerance patient population . OUTLINE : Patients stratify accord number risk factor ( 0,1 versus 2 versus 3 ) . Patients receive vinorelbine IV day 1 , 8 , 15 , 22 , 28 , 35 . Patients also receive estramustine orally twice per day day 1-7 increase dose day 8-42 . A tapered dose oral prednisone give patient elevate erythrocyte sedimentation rate . A course treatment consist 6 week treatment follow 2 week rest . Patients stable disease may receive 4 course treatment . Patients achieve partial response may undergo surgical resection follow 2 additional course treatment interleukin-2 treatment regimen . Patients complete response receive 1 additional course treatment . Patients follow death . PROJECTED ACCRUAL : A maximum 35 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic and/or recurrent renal cell carcinoma Bidimensionally measurable disease require ( outside prior radiation field ) No untreated brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No serious illness No serious active infection require therapy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior vinca alkaloid No concurrent chemotherapy Endocrine therapy : No concurrent hormone therapy No concurrent corticosteroid ( topical inhale corticosteroid allow ) Radiotherapy : At least 4 week since prior radiotherapy Less 25 % bone marrow irradiate No concurrent radiotherapy Surgery : At least 3 week since prior surgery Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>